Winmark Technology OPC

09/01/2025

Job Circular for Freshers

Position:
Jr. Executive/Executive, Business Development

Qualification:
B. Pharm/M. Pharm/M.Sc. in Chemistry/Biochemistry/Applied Chemistry from any reputed university.

Age: Not above 28.
Job Status: Full Time
Number of Vacancies: 05

Job Description:
• Dealing (sourcing raw materials) with foreign manufacturers & local pharmaceutical companies.
• Will have to build Strong interpersonal skills to develop positive, effective, & harmonious relations with local & foreign pharma companies commercial/supply chain, sales, R&D & QC working personnel.

Requirements:
• Freshers are encouraged to apply
• The candidate should be a good team player.
• Decision-making quality
• Only Male candidates are encouraged to apply
Salary: Negotiable
Job Location: Shyamoli, Dhaka.

We offer an excellent working environment, a career path, and competitive remuneration packages in the industry. Please send your updated resume with a recent passport-size photo and a cover letter to the following email address, mentioning the position in the email subject, by January 15, 2025.
email to: hrcom.agi@gmail.com

HR & Admin Department
WINMARK TECHNOLOGY OPC (A sister concern of Measab Group)
Flat 12 E, The Emporium | 14/1 Mirpur Road | Shyamoli | Dhaka-1207 | Bangladesh
www.measabgroup.com

Only short-listed candidates will be contacted for interviews. Telephone enquiries or any form of persuasion will lead to disqualification.

06/01/2025

https://lnkd.in/g5fD5NnT

Job Circular

18/07/2022

Job Post

04/10/2021

https://hotjobs.bdjobs.com/jobs/tahfizul/tahfizul1a.htm

28/07/2021

Wednesday, July 28, 2021 at 04:00 PM Central European Summer Time.

23/04/2021

Early trials show Oxford developers may have finally found an effective jab against the disease.

09/03/2021

U.S. drugmaker Merck & Co Inc said on Saturday the experimental antiviral drug molnupiravir it is developing with Ridgeback Bio showed a quicker reduction in infectious virus in its phase 2a study among participants with early COVID-19.

31/01/2021

https://tbsnews.net/thoughts/bangladesh-rising-star-pharmaceutical-finished-products-export-194416

As a developing country, Bangladesh has a successful history of exporting medicines, which might play a major role in this sector in the coming days

06/01/2021

Pfizer-BioNTech vaccine has FDA EUA.

Of course, the usual question: well, what’s IN the vaccine?

The official ingredients - with their functions:

𝐀𝐂𝐓𝐈𝐕𝐄 𝐈𝐍𝐆𝐑𝐄𝐃𝐈𝐄𝐍𝐓
- nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2

RNA is a template to produce a specific protein.
In the vaccine, this message tells our cells to produce the viral protein that will trigger the immune response to the virus.

𝐋𝐈𝐏𝐈𝐃𝐒
- (4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis (ALC-3015)
- (2- hexyldecanoate),2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
- 1,2-distearoyl-snglycero-3-phosphocholine (DSPC)
- Cholesterol

These are fancy words for 4 different fatty molecules. These assemble into capsules that contain the RNA. These fats aid in delivery and protection of the RNA.

𝐒𝐀𝐋𝐓𝐒
- potassium chloride
- monobasic potassium phosphate
- sodium chloride
- basic sodium phosphate dihydrate

Again, fancy words for 4 salts. This formula is actually phosphate-buffered saline (PBS), a common buffer. This normalizes the pH of the vaccine.

𝐒𝐔𝐆𝐀𝐑
- sucrose

Just sugar! It is a cryoprotectant to ensure the lipids don't get too sticky in ultra-cold storage.

And that’s it!

15/12/2020

“A new drug called Molnupiravir has been shown to stop the transmission of SARS-CoV-2 in 24 hours. Results of the research by scientists at the Institute of Biomedical Sciences, Georgia State University, have been published in the journal Nature Microbiology. The antiviral drug Molnupiravir, or MK-4482/EIDD-2801, is taken orally. Molnupiravir is being developed by the biotechnology firm Ridgeback Biotherapeutics in collaboration with pharmaceutical firm Merck. This is the first demonstration of an orally available drug to rapidly block SARS-CoV-2 transmission and it can be a game-changer, said Dr Richard K Plemper, Distinguished University Professor. Globally, clinical testing of Molnupiravir is carried out by Merck. The drug is now in advanced phase 2/3 human trials at multiple centres. The phase 2/3 trial is a randomised, placebo-controlled double-blind clinical study to evaluate the efficacy and safety of MK-4482 in hospitalised adults with Covid 19 across 46 locations in various countries.”

15/12/2020

Unless leaders make the right choices on recovering from the pandemic to avoid entrenching environmental problems and social inequalities, the world faces a future of lurching from crisis to crisis, reversing gains made in recent decades in health, education, social freedom and combating poverty, th...

15/12/2020

U.S. vaccine campaign launches with first shipments 'delivering hope' to millions